Clinical Trial Update: Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating induction regimens Velcade-Dex versus Velcade-Thalidomide-Dexamethasone (VTD) in newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Thalomid (thalidomide) (thalidomide)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Intergroupe Francophone du Myelome | Conditions: Multiple Myeloma | Phase 3 | Status: UNKNOWN